ClinVar Miner

Submissions for variant NM_003476.5(CSRP3):c.364C>T (p.Arg122Ter)

gnomAD frequency: 0.00001  dbSNP: rs902082118
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000413421 SCV000490928 likely pathogenic not provided 2015-04-02 criteria provided, single submitter clinical testing The R122X variant has not beenpublished as a pathogenic variant, nor has it been reported as a benign polymorphism to our knowledge. The R122Xvariant was not observed in approximately 6,500 individuals of European and African American ancestry inthe NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.R122X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. In vivo studies have shown that CSRP3 (MLP) null mice develop dilatedcardiomyopathy with hypertrophy and heart failure due to a disrupted cardiomyocyte architecture (Arberet al., 1997). Further, myocardial biopsies of a patient with HCM harboring a heterozygous CSRP3missense variant showed myocyte disarray and a significantly reduced level of MPL protein, suggestingthat cardiomyopathy may stem from CSRP3 haploinsufficiency (Geier et al., 2008). Nevertheless, the vastmajority of mutations in the CSRP3 gene reported to date are missense changes (Stenson P et al., 2014).Therefore, this variant is a strong candidate for a pathogenic variant, however the possibility that it is abenign variant cannot be excluded.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV000769302 SCV000900680 likely pathogenic Cardiomyopathy 2015-10-15 criteria provided, single submitter clinical testing
Invitae RCV001861413 SCV002195572 pathogenic Hypertrophic cardiomyopathy 12; Dilated cardiomyopathy 1M 2023-10-13 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg122*) in the CSRP3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CSRP3 are known to be pathogenic (PMID: 12642359, 14567970, 16352453, 20087448, 34558151). This variant is present in population databases (no rsID available, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 31919335, 34558151). ClinVar contains an entry for this variant (Variation ID: 372584). For these reasons, this variant has been classified as Pathogenic.
AiLife Diagnostics, AiLife Diagnostics RCV000413421 SCV002502304 uncertain significance not provided 2021-09-01 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.